Development and clinical utility of abiraterone acetate as an androgen synthesis inhibitor

A. Bryce, C. J. Ryan

Research output: Contribution to journalReview article

45 Scopus citations

Abstract

In April 2011, abiraterone acetate (AA) was approved by the US Food and Drug Administration (FDA) for the treatment of metastatic castration-resistant prostate cancer (CRPC) after chemotherapy. The development of AA is the direct result of our increased understanding of the intricacies of the androgen receptor (AR) pathway and its natural evolution in prostate cancer cells over the course of treatment. In this paper we review the biology of the AR and how it led to the rational design of AA. We also examine the clinical development of AA, its current use, and questions to be addressed for future development.

Original languageEnglish (US)
Pages (from-to)101-108
Number of pages8
JournalClinical pharmacology and therapeutics
Volume91
Issue number1
DOIs
StatePublished - Jan 1 2012

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Development and clinical utility of abiraterone acetate as an androgen synthesis inhibitor'. Together they form a unique fingerprint.

  • Cite this